capital increase

Information for shareholders about the Capital Increase, June 2015

Dear shareholders,

The main purpose of this post is to answer the enquiries and questions about the recently approved Capital Increase. Through the comments, in a collective and public way, specialized staff of Bionaturis Group will solve all the expressed questions.

Have access to must-read documents about the Capital Increase operation clicking below links:

Capital Increase Information (click here)

Relevant info: Increase of capital. Announcement in the BORME (Click here)

Relevant info: Agreement of the Board of Directors. Capital Increase (click here)

 

Find below the Capital Increase calendar

Starting the capital increase:  June 4, 2015

Negotiation period of preferential subscription rights: from 9 to 15 June (both inclusive)

Exercise period of preferential subscription rights: till July 4, 2015.

Period of discretionary assignment: July 10, 2015

Closing the capital increase: July 14, 2015

 

Yours faithfully

Victor Infante

Chief Executive Officer (CEO)

June 12th, 2015|Blog english|0 Comments|

Bionaturis launches today its capital increase

The negotiation period is between 9th until 15th June, both inclusive
The purpose is to finance the Group’s growth through the acquisition of a pharmaceutical laboratory, increasing the integration in the value chain as well as its services portfolio to third parties and the number of international clients.

Jerez, June 9th 2015. The Board of Directors of Bolsas y Mercados Españoles (BME) has agreed the listing from today Tuesday and until next Monday, June 15th, both inclusive, 4.633.036 preferential subscription rights of the Bionaturis Group that will be negotiated in the Alternative Equity Market (MAB) under the code (BNT.D).

The rights negotiation of the new Bionaturis shares falls within the subscription period, which is scheduled4th July to be over. Once completed it and if there is any shares left, discretionary assignment period will be open to place the remaining shares to other investors.

This capital increase, approved last week by the governing body of the MAB, aims to stimulate the Company’s growth process by financing the acquisition of the entire capital share of a laboratory that manufactures exclusively to third parties (Contract Manufacturing Organization).

The capital increase, that retains the preferential subscription right, involves the issue of a maximum of up to 579,129 new shares, with the same class and rights, with a par value of €0,05 per share, and a share premium of €6,95 per share. Furthermore, it was agreed to offer the new shares at a ratio of 1 new share for every eight old, free of issue expenses.

Currently the Company has a share capital of €231,651,8 consisting of 4,633,036 shares with a par value of €0,05 per share. If the increase fully subscribes, the final share capital will be €260,608,25, divided amongst 5,212,165 shares with a […]

June 9th, 2015|Blog english, Press Releases|Comments Off|

Approved the Bionaturis Group Capital Increase for a maximun of up to 579.129 new shares

The purpose is to finance the Group’s growth through the acquisition of a pharmaceutical laboratory, increasing the integration in the value chain as well as its services portfolio to third parties and the number of international clients.

After the acquisition Bionaturis Group would have a global turnover over €8 Million in the year 2016, with an EBITDA’s operating margin about 30% and employing more than 60 workers, strengthening the Group’s industrial structure.

The Company carried out another capital increase operation last April 2014 for an amount worth of €3 Million with 76% of oversubscription.

Jerez, on June 2, 2015. The Alternative Equity Market (MAB) Governing Body has approved the Document of Capital Increase (Spanish DAM) presented by Bionaturis Group in order to formalize the capital increase operation authorized by its Board of Directors last May, 14 2015. This capital increase aims to stimulate the Company’s growth process by financing the acquisition of the entire capital share of a laboratory that manufactures exclusively to third parties (Contract Manufacturing Organization).

The capital increase, that retains the preferential subscription right, involves the issue of a maximum of up to 579,129 new shares, with the same class and rights, with a par value of €0,05 per share, and a share premium of €6,95 per share. Furthermore, it was agreed to offer the new shares at a ratio of 1 new share for every eight old, free of issue expenses.

Currently the Company has a share capital of €231,651,8 consisting of 4,633,036 shares with a par value of €0,05 per share.

If the increase fully subscribes, the final share capital will be €260,608,25, divided amongst 5,212,165 shares with a par value of €0,05 each one.

The new issued shares will trade in MAB as soon as […]

June 2nd, 2015|Blog english, Press Releases|Comments Off|

Bionaturis’ new shares will start quoting at April 30

The Spanish Alternative Stock Market (MAB, in Spanish) has informed about the starting of quotation of Bionaturis’ new issued shares as a result of the just-finished capital increase.

441.241 new shares will be trading in a record time since the ending of the capital increase last April 24. The operation was fulfilled with an oversubscription of 76%.

For further information, please click here  

Bionaturis fulfilled its 3 million € increase of capital with oversubscription

Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has managed to raise 3.088.687 €, 100% of the recent increase of capital offer. It´s noteworthy that there has been an oversubscription of 76% of the total new issued shares. As a result, 441.241 new shares of a nominal value of 0.05 € each, plus an issue premium of 6.95 € have been subscribed.

It´s important to note that 74% of the final subscription has been issued by old shareholders.

After completing the process, Victor Infante, Bionaturis CEO has stated “from start to finish the whole process has surpassed our expectations. Oversubscription of 76%, the confident of old shareholders and the great potential of the new ones, even the negotiation during the pre-emptive subscription rights in the MAB have been overwhelming. On behalf of all the team we just want to say thank you for trusting in Bionaturis. This proof of confidence encourages us to implement successfully our expansion plan. We will release good news in this sense shortly.”

Purpose of the capital increase

The purpose of the capital increase is to finance the company´s internationalization plan and to undertake further investments.

 

April 24th, 2014|Press english|0 Comments|

Bionaturis’ Capital Increase

Bionaturis (BNT) will sell shares to raise money to expand its business in Latin America and Asia as it states at the Full Document of Capital Increase, published at the MAB official website. The biotech company plans to raise as much as 3 million euros from a capital increase in which it will sell new shares at 7.00 €, with a relevant premium to the current stock price. The shares have gained 136 percent this year, giving the company a market value of 52.2 million euros.

Within this post you can find the details of the capital increase operation. The below translation is intended only for information purpose. In case of any discrepancies, the official Spanish version published at the MAB and Bionaturis websites shall prevail:

Pursuant to the authorization granted by the Ordinary Shareholders’ Meeting held on June 26, 2012, pursuant to the provisions stated in Article 297.1b) of the Spanish Corporation Law (hereafter referred to as “LSC”, following the Spanish acronym), the Management Board unanimously agreed, in its session held on March 4, 2014, to increase the Company’s share capital in the terms and conditions discussed below.

 1.      Issue amount and shares to be issued.

It has been agreed to increase the company’s capital to a total amount of 231.651,80 €, by means of the issuance and release of 441.241 shares of a nominal value of 0.05 € each, plus an issue premium of 6.95 €. All shares belong to the same class and series as those currently circulating, and will be represented by book entries. The new shares shall have the same political and economic rights as those of Bionaturis that are currently circulating, as of the date when the capital increase is declared to […]

Bionaturis contributes in the MAB’s take off year

2013 will go down into history of the recently founded Alternative Spanish Stock Market (MAB) as the year in which it confirmed its take off increasing the trading volume by five fold. According to statistics published by BME, it has reached 279 million € in volume and 87 million of stock transactions.

The 23 companies listed on the MAB –among them, Bionaturis- have raised 45 million euros in the market, +12% from 2012. Last year, there were 13 capital increases and the number of trades increased by eight fold. The overall market capitalization at the end of 2013 reached 1.677 million euros, three times more than in the previous year.

The specialized media Cinco días claims Carbures as the company that has registered the top performance in the past year with 710% increase. It has been followed by other companies, accounting Gowex (nearly 500%), Ebios (148%) and Bionaturis itself, ended up the year with a global 110% rise.

2014 for the MAB has begun in an encouraging way in their first sessions, while companies are willing to continue breaking records.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR